Linagliptin

Linagliptin, the active ingredient in Linagliptin, is a DPP-4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus. It works within the glucose‑regulation pathway to lower blood sugar levels.

- Type 2 diabetes mellitus: improves glycaemic control as monotherapy. - Combination therapy with metformin: enhances overall glucose‑lowering effect. - Adjunct to lifestyle modification: supports diet and exercise in achieving target HbA1c.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory infection symptoms. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: cough, sore throat. - Dizziness: occasional light‑headedness. - Nausea: mild gastrointestinal upset. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: anaphylaxis, angioedema, or skin rash. - Hepatic injury: elevated liver enzymes or jaundice. - Stevens‑Johnson syndrome: serious skin and mucosal involvement. - Hypoglycaemia (when combined with insulin or sulfonylureas): symptomatic low blood glucose. - Bullous pemphigoid: rare autoimmune blistering skin disease.

Before initiating linagliptin, clinicians should consider several safety aspects. - Renal impairment: monitor renal function; dose adjustment usually not required but caution advised. - Hepatic impairment: use with caution and monitor liver enzymes. - Risk of hypoglycaemia: heightened when combined with insulin or sulfonylureas. - Pancreatitis: advise patients to report persistent abdominal pain. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concomitant use with insulin or sulfonylureas: increased risk of hypoglycaemia. - Strong P‑glycoprotein inhibitors (e.g., itraconazole): may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Rifampin or other enzyme inducers: may reduce linagliptin exposure. - Diuretics: potential for dehydration, monitor renal function. - ACE inhibitors or ARBs: observe for additive blood pressure effects.